Systemic inflammatory response syndrome criteria in defining severe sepsis.

BACKGROUND The consensus definition of severe sepsis requires suspected or proven infection, organ failure, and signs that meet two or more criteria for the systemic inflammatory response syndrome (SIRS). We aimed to test the sensitivity, face validity, and construct validity of this approach. METHODS We studied data from patients from 172 intensive care units in Australia and New Zealand from 2000 through 2013. We identified patients with infection and organ failure and categorized them according to whether they had signs meeting two or more SIRS criteria (SIRS-positive severe sepsis) or less than two SIRS criteria (SIRS-negative severe sepsis). We compared their characteristics and outcomes and assessed them for the presence of a step increase in the risk of death at a threshold of two SIRS criteria. RESULTS Of 1,171,797 patients, a total of 109,663 had infection and organ failure. Among these, 96,385 patients (87.9%) had SIRS-positive severe sepsis and 13,278 (12.1%) had SIRS-negative severe sepsis. Over a period of 14 years, these groups had similar characteristics and changes in mortality (SIRS-positive group: from 36.1% [829 of 2296 patients] to 18.3% [2037 of 11,119], P<0.001; SIRS-negative group: from 27.7% [100 of 361] to 9.3% [122 of 1315], P<0.001). Moreover, this pattern remained similar after adjustment for baseline characteristics (odds ratio in the SIRS-positive group, 0.96; 95% confidence interval [CI], 0.96 to 0.97; odds ratio in the SIRS-negative group, 0.96; 95% CI, 0.94 to 0.98; P=0.12 for between-group difference). In the adjusted analysis, mortality increased linearly with each additional SIRS criterion (odds ratio for each additional criterion, 1.13; 95% CI, 1.11 to 1.15; P<0.001) without any transitional increase in risk at a threshold of two SIRS criteria. CONCLUSIONS The need for two or more SIRS criteria to define severe sepsis excluded one in eight otherwise similar patients with infection, organ failure, and substantial mortality and failed to define a transition point in the risk of death. (Funded by the Australian and New Zealand Intensive Care Research Centre.).

[1]  Jonathan Fielden,et al.  An evaluation of systemic inflammatory response syndrome signs in the Sepsis Occurrence in Acutely ill Patients (SOAP) study , 2006, Intensive Care Medicine.

[2]  Norbert Lameire,et al.  Notice , 2012, Kidney International Supplements.

[3]  Rinaldo Bellomo,et al.  Development and implementation of a high-quality clinical database: the Australian and New Zealand Intensive Care Society Adult Patient Database. , 2006, Journal of critical care.

[4]  M. Bailey,et al.  The Australian and New Zealand Risk of Death (ANZROD) model: getting mortality prediction right for intensive care units. , 2014, Critical care and resuscitation : journal of the Australasian Academy of Critical Care Medicine.

[5]  I. Douglas,et al.  Sensitivity of systemic inflammatory response syndrome for critical illness among ED patients. , 2014, The American journal of emergency medicine.

[6]  J. Vincent,et al.  Dear SIRS, I'm sorry to say that I don't like you... , 1997, Critical care medicine.

[7]  J. E. Carceller.  American College of Chest Physicians/Society of Critical Care Medicine Consensus Conference: Definitions for sepsis and organ failure and guidelines for the use of innovative therapies in sepsis , 1992, Critical care medicine.

[8]  Mitchell M. Levy,et al.  2001 SCCM/ESICM/ACCP/ATS/SIS International Sepsis Definitions Conference , 2003, Intensive Care Medicine.

[9]  J. Vincent,et al.  Effect of eritoran, an antagonist of MD2-TLR4, on mortality in patients with severe sepsis: the ACCESS randomized trial. , 2013, JAMA.

[10]  Derek Bell,et al.  Trial of early, goal-directed resuscitation for septic shock. , 2015, The New England journal of medicine.

[11]  F. Epelde.  [Hydroxyethyl starch 130/0.42 versus Ringer's acetate in severe sepsis]. , 2013, Revista clinica espanola.

[12]  D. Annane,et al.  Tight Glycemic Control in Critically Ill Patients—Reply , 2010 .

[13]  C. Brun-Buisson,et al.  EPISEPSIS: a reappraisal of the epidemiology and outcome of severe sepsis in French intensive care units , 2004, Intensive Care Medicine.

[14]  E. Ruokonen,et al.  Incidence, treatment, and outcome of severe sepsis in ICU-treated adults in Finland: the Finnsepsis study , 2007, Intensive Care Medicine.

[15]  J. Vincent,et al.  The SOFA (Sepsis-related Organ Failure Assessment) score to describe organ dysfunction/failure , 1996, Intensive Care Medicine.

[16]  D. Pittet,et al.  The natural history of the systemic inflammatory response syndrome (SIRS). A prospective study. , 1995, JAMA.

[17]  D. Annane,et al.  Corticosteroid treatment and intensive insulin therapy for septic shock in adults: a randomized controlled trial. , 2010, JAMA.

[18]  J. le Gall,et al.  Systemic inflammatory response and progression to severe sepsis in critically ill infected patients. , 2005, American journal of respiratory and critical care medicine.

[19]  B. Carr,et al.  Benchmarking the Incidence and Mortality of Severe Sepsis in the United States* , 2013, Critical care medicine.

[20]  Kevin J. Tracey,et al.  Sepsis definitions: time for change , 2013, The Lancet.

[21]  Michael Bailey,et al.  Goal-directed resuscitation for patients with early septic shock. , 2014, The New England journal of medicine.

[22]  W. Knaus,et al.  Definitions for sepsis and organ failure and guidelines for the use of innovative therapies in sepsis. The ACCP/SCCM Consensus Conference Committee. American College of Chest Physicians/Society of Critical Care Medicine. , 1992, Chest.

[23]  V. Pettilä,et al.  Lower versus higher hemoglobin threshold for transfusion in septic shock. , 2014, The New England journal of medicine.

[24]  M. Bailey,et al.  Performance of Apache III over Time in Australia and New Zealand: A Retrospective Cohort Study , 2012, Anaesthesia and intensive care.

[25]  Andrew Rhodes,et al.  Drotrecogin alfa (activated) in adults with septic shock. , 2012, The New England journal of medicine.

[26]  N. Khardori.  Hydrocortisone Therapy for Patients with Septic Shock , 2008 .

[27]  R. Bellomo,et al.  Mortality related to severe sepsis and septic shock among critically ill patients in Australia and New Zealand, 2000-2012. , 2014, JAMA.

[28]  Michael Bailey,et al.  Risk prediction of hospital mortality for adult patients admitted to Australian and New Zealand intensive care units: development and validation of the Australian and New Zealand Risk of Death model. , 2013, Journal of critical care.